CD34+ Stem Cell Infusion to Augment Graft Function

Status Terminated

Clinical Trial Summary

The purpose of this study is to determine if infusing additional special donor cells will help to improve graft or immune function in previously transplanted children with immune deficiencies and bone marrow failures.

Clinical Trial Description

The purpose of this study is to investigate the usefulness of infusing purified CD34+ cells of donor origin in order to augment graft function in response to declining chimerism after initially performing an allogeneic hematopoietic stem cell transplant (HSCT) for children with primary immunodeficiency diseases. This protocol will be utilized for patients with waning mixed donor chimerism that is inadequate for correction of clinical condition or disease for which stem cell transplant was performed, or for augmentation of immune function. An infusion of selected CD34+ stem cells will be given without any preparative regimen. As the children eligible for this protocol have reduced immune function and pre-existing donor chimerism, we hypothesize that stem cells will be able to engraft and the infusion will augment graft function. This therapy serves as an alternative to a second stem cell transplant that is known to be associated with significant morbidity and mortality. CD34+ stem cells will be collected from the donor used for initial stem cell transplant. Cells will be T-cell depleted (TCD) by performing a CD34 selection using the CliniMACS device (Miltenyi Biotec) in order to prevent development of new or exacerbation of existing graft versus host disease (GVHD), as avoidance of GVHD in nonmalignant diseases is desirable. There is sufficient data showing that mixed donor chimerism is adequate for reverting disease phenotype in certain primary immunodeficiencies. Observations from Europe and CCHMC show that donor chimerism might be boosted by CD34+ stem cell infusion alone without any specific preparative regimen. This therapy is likely to be associated with low toxicity due to the absence of a preparative regimen and lack of exposure to fresh donor cells capable of initiating GVHD, and offers potential significant benefit. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01856582
Study type	Interventional
Source	Children's Hospital Medical Center, Cincinnati
Contact
Status	Terminated
Phase	Phase 2
Start date	October 2010
Completion date	August 15, 2018

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT03249129` - Identification of Autoantibodies and Autoantigens in the Cerebrospinal Fluid of Patients With Spinal Cord Trauma
Completed	`NCT02833805` - NMA Haplo or MUD BMT for Newly Diagnosed Severe Aplastic Anemia	Phase 2
Completed	`NCT01049854` - CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant	Phase 2
Recruiting	`NCT04644016` - Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders	Phase 2
Recruiting	`NCT03579875` - Alpha/Beta TCD HCT in Patients With Inherited BMF Disorders	Phase 2
Recruiting	`NCT01019876` - Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases	Phase 2/Phase 3
Withdrawn	`NCT03086252` - Patient-Driven Transfusion Thresholds in Hematological Disorders: A Pilot Study	N/A
Active, not recruiting	`NCT01642979` - Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria	Phase 2
Recruiting	`NCT06250595` - European Rare Blood Disorders Platform (ENROL)
Active, not recruiting	`NCT01760096` - Safety and Efficacy of Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013)	Phase 2
Recruiting	`NCT04232085` - Reduced Intensity BMT for Immune Dysregulatory and Bone Marrow Failure Syndromes Using Post-Transplant Cyclophosphamide	Phase 2
Recruiting	`NCT03622788` - Cytokine-Treated Veto Cells in Treating Patients With Hematologic Malignancies Following Stem Cell Transplant	Phase 1/Phase 2
Terminated	`NCT00968864` - T-cell Depleted Alternative Donor Transplantation	Phase 2
Recruiting	`NCT04211714` - Study to Evaluate of EXG34217 in Patients With Telomere Biology Disorders With Bone Marrow Failure	Phase 1
No longer available	`NCT01200017` - Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.